Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Preferred Shares (2016 - 2025)

Iovance Biotherapeutics has reported Preferred Shares over the past 8 years, most recently at $2000.0 for Q4 2025.

  • Quarterly results put Preferred Shares at $2000.0 for Q4 2025, down 33.33% from a year ago — trailing twelve months through Dec 2025 was $2000.0 (down 33.33% YoY), and the annual figure for FY2025 was $2000.0, down 33.33%.
  • Preferred Shares for Q4 2025 was $2000.0 at Iovance Biotherapeutics, roughly flat from $2000.0 in the prior quarter.
  • Over the last five years, Preferred Shares for IOVA hit a ceiling of $3000.0 in Q4 2023 and a floor of $2000.0 in Q1 2025.
  • Median Preferred Shares over the past 3 years was $3000.0 (2023), compared with a mean of $2600.0.
  • Biggest five-year swings in Preferred Shares: changed 0.0% in 2024 and later crashed 33.33% in 2025.
  • Iovance Biotherapeutics' Preferred Shares stood at $3000.0 in 2023, then changed by 0.0% to $3000.0 in 2024, then tumbled by 33.33% to $2000.0 in 2025.
  • The last three reported values for Preferred Shares were $2000.0 (Q4 2025), $2000.0 (Q1 2025), and $3000.0 (Q4 2024) per Business Quant data.